– Livongo has been awarded a contract to provide the Livongo for Diabetes solution to eligible members covered by the Federal Employees Health Benefits Program (FEHBP ) under one health plan.
– The contract is Livongo’s biggest contract in company history and will account for $20-25M in revenue in 2020 and $30-35M in revenue for 2021, representing a total of $50-60M including both years.
– The announcement reflects Livongo’s overall market traction and how they are expanding from working primarily with self-insured employers, to broader and larger markets including government employees, labor unions, and fully-insured populations.
Livongo Health, Inc (Nasdaq: LVGO), an Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced it was awarded a contract to provide the Livongo for Diabetes solution to eligible members covered by the Federal Employees Health Benefits Program (FEHBP) who are living with Type 1 or Type 2 diabetes under one health plan covering 5.3 million federal employees, retirees, and their families out of the nearly 8 million people who receive their benefits through the FEHBP.
Largest Contract in Company History Makes Livongo for Diabetes a Covered Benefit
Livongo signed a two-year agreement which will launch the Livongo for Diabetes program starting on January 1, 2020, and expects a 9 to 12-month deployment period to those eligible members living with diabetes. Livongo expects that this agreement will add approximately 25,000 Livongo for Diabetes Members in 2020, growing to approximately 45,000 Members in 2021. This is larger than the expectation of 20,000 to 30,000 total Members previously disclosed by Livongo. Based on this updated expected enrollment, Livongo anticipates the contract through the FEHBP will account for $20-25M in revenue in 2020 and $30-35M in revenue for 2021, representing a total of $50-60M including both years.
Contract Opens Government Sector Business for Livongo
The new contract reflects Livongo’s overall market traction and how they are expanding from working primarily with self-insured employers, to broader and larger markets including government employees, labor unions, and fully-insured populations. Livongo’s Applied Health Signals platform leverages advanced technology and data science to understand people’s unique health needs and then provide clinically-based guidance, or Health NudgesTM, to drive positive behavior change. The Livongo for Diabetes solution leads to higher Member satisfaction, improved clinical outcomes, and lower overall healthcare spending.
A 2019 study demonstrated that 94 percent of Livongo for Diabetes program Members who completed a program survey achieved improved Diabetes Empowerment Scale – Short Form (DES-SF) or Diabetes Distress Scale 2 (DDS2) in year one of the Livongo for Diabetes Program; effectively improving confidence in diabetes self-management, while decreasing burnout related to diabetes management. A separate 2019 study published in the Journal for Medical Economics showed that the Livongo for Diabetes program delivered an $88 per Member per month reduction in medical spending for Livongo Members when compared to the matched non-Livongo population and that employers experienced a positive return on investment in one year.
“This win highlights two of our competitive advantages. First, government entities and large plans want to see multi-year, clinically validated results at scale and only Livongo has that independently validated data. Second, our AI+AI engine, which aggregates information from our own devices, electronic health records, pharmacy records, smart watches, and continuous glucose monitors interprets that information, applies it back to our Members to learn what works, and then iterates using Health Nudges™, is making us smarter and more Member focused every day,” said Dr. Jennifer Schneider, M.D., M.S., President of Livongo.
